Scott Filler, M.D. is Professor of Medicine, David Geffen School of Medicine, and Chief, Division of Infectious Diseases, Harbor-UCLA Medical Center. He completed his undergraduate education at Dartmouth College in Hanover, New Hampshire, where he graduated Magna cum Laude.  He then received his medical degree from the UCLA School of Medicine, and performed an internship and residency in internal medicine before completing a fellowship in infectious diseases at Harbor-UCLA Medical Center.  His research focuses on the mechanisms by which pathogens including Candida albicans and Aspergillus fumigatus invade and damage human cells, causing life-threatening infections.  Dr. Filler and his team discovered the first two fungal invasins.  Dr. Filler has authored or co-authored more than 150 peer-reviewed papers, book chapters and reviews. He is inventor on 3 U.S. patents of pharmaceutical compositions to vaccinate against disseminated candidiasis.

Mike Gresser, Ph.D. is Chief Scientific Officer for ImmuneGene, the Myelin Repair Foundation, and is a Lecturer in the Honors Program in the College of Letters and Science at UCLA. He serves on or chairs the scientific advisory boards of several biotechnology companies. From 2000-2006, Dr. Gresser served as Vice President, Research for Inflammation at Amgen, Inc. Prior to Amgen, he was at the Merck Frosst Center for Therapeutic Research where he rose to be Executive Director of Biochemistry and Molecular Biology. His team was responsible for the introduction of Singulair, Vioxx, and Arcoxia to the clinical market. Dr. Gresser received his Ph.D in Biochemistry from Brandeis University and did postdoctoral studies at the Molecular Biology Institute at UCLA under Nobel Laureate Paul D. Boyer. Before joining Merck Frosst in 1988, Dr. Gresser was Professor of Chemistry at Simon Frazer University in Burnaby, British Columbia where he was on the faculty for 8 years.